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Abstract
Background: Maturity-onset of the young (MODY) is a clinically heterogeneous form of diabetes characterized by an
autosomal-dominant mode of inheritance, an onset before the age of 25 years, and a primary defect in the pancreatic beta-
cell function. Approximately 30% of MODY families remain genetically unexplained (MODY-X). Here, we aimed to use whole-
exome sequencing (WES) in a four-generation MODY-X family to identify a new susceptibility gene for MODY.
Methodology: WES (Agilent-SureSelect capture/Illumina-GAIIx sequencing) was performed in three affected and one non-
affected relatives in the MODY-X family. We then performed a high-throughput multiplex genotyping (Illumina-GoldenGate
assay) of the putative causal mutations in the whole family and in 406 controls. A linkage analysis was also carried out.
Principal Findings: By focusing on variants of interest (i.e. gains of stop codon, frameshift, non-synonymous and splice-site
variants not reported in dbSNP130) present in the three affected relatives and not present in the control, we found 69
mutations. However, as WES was not uniform between samples, a total of 324 mutations had to be assessed in the whole
family and in controls. Only one mutation (p.Glu227Lys in KCNJ11) co-segregated with diabetes in the family (with a LOD-
score of 3.68). No KCNJ11 mutation was found in 25 other MODY-X unrelated subjects.
Conclusions/Significance: Beyond neonatal diabetes mellitus (NDM), KCNJ11 is also a MODY gene (‘MODY13’), confirming
the wide spectrum of diabetes related phenotypes due to mutations in NDM genes (i.e. KCNJ11, ABCC8 and INS). Therefore,
the molecular diagnosis of MODY should include KCNJ11 as affected carriers can be ideally treated with oral sulfonylureas.
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Introduction
Maturity-onset of the young (MODY) is an early-onset non
autoimmune form of diabetes with a autosomal-dominant mode of
transmission [1]. MODY represents less than 2% of all non
autoimmune diabetes cases and it usually develops during
childhood or young adulthood [1]. This monogenic disorder is
due to primary dysfunction of pancreatic beta-cells and it is rarely
associated with obesity that is not required for its development, in
contrast to most common forms of type 2 diabetes [1].
MODY is not a single entity as at least twelve MODY subtypes
with distinct genetic aetiologies have been reported in the
literature: MODY1-HNF4A, MODY2-GCK, MODY3-HNF1A,
MODY4-PDX1, MODY5-HNF1B, MODY6-NEUROD1,
MODY7-KLF11, MODY8-CEL, MODY9-PAX4, MODY10-INS,
MODY11-BLK and very recently MODY12-ABCC8 [1,2,3].
These distinct aetiologies are associated with substantial differ-
ences in clinical course, in terms of age of onset and level of
hyperglycemia, explaining various responsiveness to treatment
[3,4]. Therefore, an early molecular diagnosis is crucial as it leads
PLoS ONE | www.plosone.org 1 June 2012 | Volume 7 | Issue 6 | e37423to accurate diabetes treatment and care management of the
patient and his family, with estimation of diabetes risk for the
asymptomatic relatives [4].
However, despite previous intensive linkage analyses and
candidate gene screening, approximately 30% of MODY families
from our French study cohort remain genetically unexplained
(MODY-X) [1]. Recently, next-generation sequencing (NGS), in
particular whole-exome sequencing (WES) which is the targeted
sequencing of the human genome subset that is protein coding, has
become a highly powerful and efficient strategy for identifying
novel causative genes for complex disorders, although mostly
monogenic so far [5]. Indeed, in less than three years, WES has
been used to identify causative genes for several dozens of
Mendelian disorders [5]. Recently, we provided proof-of-concept
that WES can be used as a clinical tool for assessing patients
presenting with an undiagnosed neonatal diabetes mellitus (NDM)
that is another monogenic form of non autoimmune diabetes [6].
As WES typically identifies dozens of thousands exomic variants, a
selection strategy has to be used in order to facilitate the
identification of the only mutation that causes the disease [5,6].
With regard to MODY, WES analysis of several affected and
healthy relatives from a MODY family may be powerful for
identifying new susceptibility genes.
In the present study, we sequenced the exome of four relatives
(three MODY patients and one healthy member) from a large
French MODY-X family. After a filtering strategy of the identified
variants and an additional genotyping of putatively causal
mutations in the extended MODY-X family, we identified the
thirteenth MODY gene.
Results
We analysed a four-generation MODY-X family including 12
affected members, one member with impaired fasting glucose, one
member with impaired glucose tolerance, one member with
documented type 1 diabetes and 22 non-affected relatives
(Figure 1). Of note, no member of the family showed NDM.
We sequenced the exome of four members from this family: a
diabetic patient diagnosed at 17 years, his diabetic father
diagnosed at 20 years, his non-affected mother and his diabetic
cousin diagnosed at 13 years (Figure 1, Table 1).
After target enrichment, whole exome DNA libraries from the
four relatives were sequenced in 76 bp paired-end reads, using two
channels of the GAIIx, achieving a mean depth of coverage
between 90.8 and 125.76 (Table 2). Depending on the Agilent
capture we used (38 Mb or 50 Mb) and probably on the DNA
quality, we found between 45,124 and 92,768 variants per exome
(Table 2). By focusing on variants of interest, i.e. non-synonymous
and splice-site variants, gains of stop codon or frameshift
mutations, it remained between 7,925 and 11,632 variants,
including 540 and 882 variants not reported in the database
dbSNP130, respectively (Table 2). Subsequently, we identified
839 variants of interest present in the three affected relatives (IV4,
III5 and IV5, Figure 1) and not present in the non-affected family
member (III6, Figure 1), of which 69 were not reported in the
database dbSNP130 (Table 3). Therefore, it was probable that
the causal mutation for MODY was included in this set of 69
mutations. However, we found that the depth of coverage was not
uniform, depending on the DNA sample (and not only on the
Agilent capture version). Indeed, for instance, we identified a total
of 210 variants of interest (of which 34 were not reported in
dbSNP130) in the affected member III5, which could not be called
in the affected member IV4, as depth of coverage was below 86at
the related loci (see combinations #4 and #6i nTable 3).
Therefore, at this stage, we were not able to know if the affected
member IV4 also carried this set of mutations. As the exome of the
affected member IV5 was performed with the Agilent capture
‘50 Mb’ (instead of ‘38 Mb’ for the affected members IV4 and
III5), we identified lots of variants for this family member (2,625
variants of interest of which 209 were not reported in dbSNP130)
that could not be called in the affected members IV4 and III5 (see
combination #7i nTable 3). Therefore, at this stage, it was also
impossible to know if the two other affected members carried these
mutations. Finally, by taking into account all the possible
combinations in the three affected members, we identified a total
of 324 putatively causal mutations for MODY (not present in the
non-affected member III6 and not reported in dbSNP130)
(Table 3).
By using an Illumina GoldenGate assay, we assessed the
presence of this set of 324 mutations in the whole family (23
additional DNA samples were available, Figure 1) and in 406
European adults (.47 years old), from the French D.E.S.I.R.
study, which presented with normal fasting plasma glucose.
Among mutations that were not present in the 406 controls, only
one mutation (at a heterozygous state) was present in the eight
relatives with overt non autoimmune diabetes (II1, III3, III5, III9,
III11, IV4, IV5 and V1, Table 1, Figure 1). This mutation was
also carried by a prediabetic member (IV2), his non-diabetic
brother (IV1) and two non-diabetic children (V3 and V4)
(Table 1, Figure 1). All the other non-diabetic members (III1,
III2, III4, III6, III7, III8, III10, III12, IV3, IV6, IV7, IV9, IV10
and V2) and the type 1 diabetic member (IV8) did not carry the
mutation (Table 1, Figure 1). This mutation is a non-
synonymous variant (c.679G.A; p.Glu227Lys) located in the
KCNJ11 gene (NM_000525.3).
We then performed a linkage analysis using a dominant
parametric model based on three age-dependent liability classes
(,13, 13–39 and $40 years old). We found a maximum LOD
score of 3.68 at the locus of KCNJ11 p.Glu227Lys mutation
(chromosome 11p15.1), following a two-point or multipoint
analysis (Figure 2). Under a non-parametric linkage (NPL)
model, we found a maximum NPL score of 4.65 (P =0.001) and
4.42 (P =0.00005) at the locus of the mutation, following two-
point and multipoint analyses, respectively. Therefore, it is highly
probable that KCNJ11 p.Glu227Lys mutation is causal for MODY
in the analyzed pedigree. Of note, we previously missed this
linkage peak [7] as family member IV8 had been erroneously
considered as a MODY patient while he had type 1 diabetes.
Indeed, in mid 2011, we found a positivity for GAD autoanti-
bodies from a serum sample collected in 1996, and the patient was
found to carry HLA class II (DRB1*04) alleles which confer
susceptibility to type 1 diabetes.
We sequenced KCNJ11 in 22 other French MODY-X unrelated
probands, and we did not identify any non-synonymous variant
that was not reported in the public database dbSNP130 (data not
shown), implying that KCNJ11 is rarely mutated in French MODY
families.
Discussion
The present study based on WES, high-throughput multiplex
genotyping and linkage analysis, unambiguously identified the
thirteenth MODY gene, KCNJ11 that encodes pore-forming
KIR6.2 subunit of the pancreatic beta-cell ATP-dependent
potassium (K-ATP) channel. The K-ATP channel that is a
hetero-octamer consisting of four KIR6.2 subunits and four
sulfonylurea receptor 1 (SUR1) subunits (encoded by ABCC8),
links cellular nutrient metabolism to membrane electrical activity,
KCNJ11, the Thirteenth MODY Gene
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a key role in insulin secretion [8]. Approximately 35% of patients
with NDM have a gain-of-function mutation in KCNJ11 or in
ABCC8 [1]. Importantly, most NDM patients who carry a K-ATP
channel mutation can successfully be transferred from insulin
therapy to oral sulfonylureas [9,10]. Therefore, in this newly
elucidated French MODY family, it will be crucial to adjust the
treatment of all relatives with non autoimmune diabetes, in
particular member V1 who is currently treated by insulin
(Table 1, Figure 1) and members III11 and IV5 who show a
quite bad metabolic control (Table 1, Figure 1). Importantly, the
affected member III3 who also carries the mutation and who has
always been treated by oral sulfonylureas, shows a perfect
metabolic control at 73 years (HbA1c =5.7% and fasting plasma
glucose =5.0 mmol/l, after a duration of diabetes of diabetes;
Table 1, Figure 1). It confirms recent data obtained in NDM
patients showing that after a follow up of 68 months, sulfonylureas
are still active in patients with KCNJ11 mutations, ruling out the
hypothesis of a long term toxicity of this drug on pancreatic beta-
cells [11].
The presently identified KCNJ11 p.Glu227Lys mutation has
already been reported in the literature [12,13,14,15,16,17,18].
The mutation is known to cause transient NDM (with diabetes
relapse before 10 years old in most cases) and it has been reported
to arise de novo [13,14] or to be transmitted from one of both
parents who presented with a transient NDM [13] or with other
form of non autoimmune young-onset diabetes [12,15,17,18]. A
study reported that the p.Glu227Lys mutation has a functional
effect: it reduces the sensitivity of the K-ATP channel to inhibition
by MgATP, and enhances the intrinsic open probability of the K-
ATP channel, in Xenopus oocytes expressing the mutant (at the
heterozygous state) [16].
KCNJ11 gene screening is currently indicated by guidelines in
all patients who present with diabetes diagnosed before 6–12
months of age [6,19,20]. Some studies reported that families of
patients with a transient or permanent form of NDM due to a
KCNJ11 mutation can also include other carriers in the family with
childhood or later-onset diabetes (age of diagnosis before 30 years)
[17,21,22]. However, no previous study has ever described a
family with a well-defined MODY due to a KCNJ11 mutation.
Furthermore, our MODY family does not include any member
who presented with NDM. Therefore, since the affected carriers of
a KCNJ11 mutation should ideally receive oral sulfonylureas, the
routine genetic diagnosis of MODY families should now include
KCNJ11, even if the prevalence of KCNJ11 mutations in MODY
seems quite low. Indeed, we did not identify any other KCNJ11
mutation in our MODY-X families. Furthermore, Bowman et al.
sequenced both ABCC8 and KCNJ11 genes in 85 patients who had
been referred for genetic testing for MODY and who were
sensitive to (or treated with) oral sulfonylureas, and they did not
identify any mutation in KCNJ11 [2]. Even if we actually found
one MODY family only with a KCNJ11 mutation, so far, the true
Figure 1. Pedigree of the family showing diabetes status of each member, as well as genetic status, age of diagnosis, treatment and
date of birth. With regard to the genetic status, NM denotes the presence of the heterozygous KCNJ11 p.Glu227Lys mutation and NN denotes the
absence of mutation at the same locus. Circles represent female participants and squares male participants. A slash through the symbol indicates that
the family member is deceased. Black symbols indicate patients with non autoimmune diabetes. The half-filled and quarter-filled symbols indicate
individuals with impaired glucose tolerance and impaired fasting glucose, respectively. The black symbols with a white diagonal denote patients with
type 1 diabetes. Green arrows point to members for whom the whole-exome was sequenced. INS, insulin; OHA, oral hypoglycaemic agents; SU,
sulfonylurea.
doi:10.1371/journal.pone.0037423.g001
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(with young adult onset patients). Assessing a putative MODY13
in such families can be very helpful for a more personalized
treatment of their specific form of diabetes.
Importantly, our study firmly confirms that KCNJ11 mutations
can be associated with a large spectrum of diabetes phenotypes
and can be not totally penetrant. Indeed, member IV1 of our
French MODY family, who carries the KCNJ11 p.Glu227Lys
mutation, has normal fasting plasma glucose level at 39 years
(5.3 mmol/l, Table 1, Figure 1). This phenotypic spectrum of
diabetes has also been reported in carriers of a mutation in ABCC8
[2,23] or in the insulin (INS) gene [24,25,26,27], which both
represent, with KCNJ11, the most frequently mutated genes in
patients with NDM [1]. Epigenetic effects or other modifier
genetic effects could explain the substantial difference in both
diabetes onset and clinical expression between NDM and MODY
patients.
Some lessons can be obtained from the present study. At
present, although the WES technology is highly powerful and
quickly led to the elucidation of several dozens of syndromes, it
does not provide a perfect sequencing. Indeed, even with a mean
depth of coverage higher than 906, WES is not uniform between
samples and has lots of gaps. Therefore, when the analysis is based
on WES from several affected relatives, an additional genotyping is
necessary in order to avoid any false negative result. For a
molecular diagnosis of MODY based on NGS, a targeted
sequencing (by hybridization or using a droplet-based PCR
technology) of all MODY genes, including NDM genes as they
are also responsible for other forms of diabetes, may be more
accurate at present. As WES technology is improving day after
Table 2. Number of variants identified through the WES analysis of the four DNA samples.
Members IV4 (affected) III5 (affected) III6 (control) IV5 (affected)
Agilent capture used (Mb) 38 38 38 50
Sequenced regions with coverage $86(Mb) 34.2 34.2 35.2 45.0
Mean depth of coverage (6) 90.8 104.4 125.7 95.9
Total targeted variants
a Homozygous (Novel) 18,163 (531) 20,461 (817) 26,475 (1,301) 36,637 (1,999)
Heterozygous (Novel) 26,961 (3,048) 30,574 (4,195) 39,056 (5,769) 56,131 (7,078)
Splice-site variants (including indels) Homozygous (Novel)5 2 6 ( 9) 577 (9)6 2 3 ( 12) 738 (12)
Heterozygous (Novel)6 9 1 ( 57) 777 (77)9 5 1 ( 96) 1,099 (109)
Non-synonymous variants Homozygous (Novel) 2,702 (24) 2,952 (26) 3,119 (34) 3,735 (36)
Heterozygous (Novel) 3,954 (441) 4,417 (504) 4,845 (528) 5,917 (666)
Non-synonymous variants leading
to a gain of STOP codon
Homozygous (Novel)8 ( 1)9 ( 0)1 0 ( 2)1 6 ( 1)
Heterozygous (Novel)4 0 ( 4)4 3 ( 9)5 3 ( 7)8 2 ( 14)
Frameshift variants Homozygous (Novel)3 ( 3)4 ( 4)1 3 ( 13)3 7 ( 36)
Heterozygous (Novel)1 ( 1)2 ( 2)3 ( 2)8 ( 8)
Frameshift variants leading
to a gain of STOP codon
Homozygous (Novel)0 ( 0)0 ( 0)0 ( 0)0 ( 0)
Heterozygous (Novel)0 ( 0)1 ( 1)0 ( 0)0 ( 0)
aThis includes all identified variants (including insertion or deletion) that reach the quality threshold and with depth of coverage $86; Novel means not present in the
public database dbSNP130; Indel, insertion or deletion.
doi:10.1371/journal.pone.0037423.t002
Table 3. Estimation of number of variants to be assessed by genotyping in the extended family and in controls.
Depth of coverage
Combination Member IV4 Member III5 Member IV5
Number of variants of interest
a, not
present in member III6=(1) (1) - variants present in dbSNP130
1 $86 $86 $86 839 69
2 $86 $86 ,86 13 7
3 $86 ,86 $86 16 2
4 ,86 $86 $86 121 9
5 $86 ,86 ,86 33
6 ,86 $86 ,86 89 25
7 ,86 ,86 $86 2,625 209
TOTAL: 3,706 324
aVariants of interest are non-synonymous mutations, splice site mutations, gains of STOP codon. No frameshift mutation was found in any of the combinations.
doi:10.1371/journal.pone.0037423.t003
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Materials and Methods
Study Participants
The French MODY-X family (named F725) was recruited by
the CNRS UMR8199 unit in 1996 [28], and it has regularly been
extended since this date, with updated clinical data for all relatives
(last update was performed in mid 2011) (Table 1). A pedigree of
the family is shown in Figure 1. Of note, no member of the family
showed NDM. In the proband of the family, we previously
searched for mutations in the known susceptibility genes for
MODY: HNF4A, GCK, HNF1A, HNF1B, PDX1, KLF11, BLK, INS
and ABCC8. All these genetic screenings were performed by a
standard Sanger sequencing method. No putatively causal
mutations were identified.
We assessed the candidate mutations in 406 normal glucose
French adults (.47 years old) from the Data from the
Epidemiological Study on the Insulin Resistance Syndrome
(D.E.S.I.R.) cohort. The D.E.S.I.R. study is a longitudinal French
general population cohort, fully described elsewhere [29].
For KCNJ11 gene screening, we used DNA samples from a total
of 22 unrelated French probands presenting with MODY-X
following these criteria: i/presence of overt diabetes in at least
three consecutive generations with a dominant transmission and/
or at least two diabetic patients diagnosed before age 25 years; ii/
no requirement for insulin therapy during the first two years after
diagnosis, or measurable C-peptide several years after diagnosis;
and iii/absence of auto-immunity markers. These subjects were
recruited by the CNRS UMR8199 unit. Glycemic status for non-
MODY individuals was defined according to 1997 American
Diabetes Association or 1999 World Health Organization criteria:
normal glucose defined as fasting glucose ,6.1 mmol/l without
hypoglycemic treatment; impaired fasting glucose defined as
fasting glucose between 6.1 and 7.0 mmol/l, without hypoglyce-
mic treatment; impaired glucose tolerance defined as glucose
concentration 2 h after an oral glucose load between 7.8 and
11.1 mmol/l; and T2D defined as fasting glucose $7.0 mmol/l
and/or treatment with antidiabetic agents.
All DNA samples used for the present study were extracted from
blood.
The study was approved by the local ethics committees (CNIL
[Commission Nationale de l’Informatique et des Liberte ´s]
#901060 and CCPPRB [Comite ´ Consultatif de Protection des
Personnes dans la Recherche Biome ´dicale] of Lille and Paris).
Each participant gave written informed consent. With regard to
child participant, both parents gave written informed consent for
the genetic testing of their child.
Targeted Capture and Massive Parallel Sequencing
Approximately 99.18% of CCDS exons or 98.75% of RefSeq
exons from 3 mg of genomic DNA were captured using the Agilent
SureSelect Human All Exon Kit (‘38 Mb’ kit for members III5,
III6 and IV4, and ‘50 Mb’ kit for member IV5), following the
manufacturer’s protocols (Agilent, Santa Clara, CA, USA). Briefly,
DNA was sheared by acoustic fragmentation (Bioruptor NGS,
Diagenode, Lie `ge, Belgium) and purified using Agencourt
AMPure XP beads (Beckman Coulter, Fullerton, CA, USA).
The quality of the fragmentation and purification was assessed
with the Agilent 2100 Bioanalyzer. The fragment ends were
repaired and adaptors were ligated to the fragments. The resulting
Figure 2. Multipoint linkage analysis following a dominant parametric model in the French pedigree. The positions of the genetic
markers are ordered from chromosome 11p15.5 to 11q12.2 (chr11:1,820,211–59,856,421; positions given according to human genome assembly
GRCh37/hg19).
doi:10.1371/journal.pone.0037423.g002
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amplified by PCR and captured by hybridization to the
biotinylated RNA library baits. Bound genomic DNA was purified
with streptavidin coated magnetic Dynabeads (Invitrogen, Carls-
bad, CA, USA) and re-amplified. The whole-exome DNA library
was sequenced on the Illumina Genome Analyzer IIx (GAIIx) in
76 base-pairs (bp) paired-end reads and using two channels
(Illumina, San Diego, CA, USA).
Sequence Reads Mapping and Variant Calling
Sequence reads were mapped to the reference human genome
(UCSC NCBI36/hg18) using the ELANDv2 software (Illumina).
Variant detection was performed with the CASAVA software
(version 1.6, Illumina) and filtered to fit a CASAVA quality
threshold $10 and depth of $86. CASAVA filters duplicate reads
and reads without matched pairs.
Genotyping of the 324 Candidate Mutations in the Whole
Family and in Controls
To validate mutations obtained by WES, we used a multiplex
high-throughput single nucleotide polymorphism (SNP) detection
assay based on Golden Gate technology (Illumina), allowing the
genotyping of 324 SNPs in a total of 433 DNA samples (27
members of the MODY family and 406 normal glucose
individuals from the D.E.S.I.R. cohort study). The two-day
protocol was performed according to the manufacturer’s recom-
mendations. Veracode BeadXpress Reader scanned each 96-well
reaction plate (Illumina). All the generated data were processed
using GenomeStudio 1.8 Software (Illumina) to infer all SNP
genotypes via three clusters on a graph based on the fluorescence
obtained.
Sanger Sequencing
Approximately 8% of the mutations found in WES could not be
designed by the Illumina BeadXpress Assay Design Tool because
of technical issues (e.g. another SNP very closed to the targeted
SNP, high GC content, CNV or repeat region). In these cases,
confirmation of SNPs was realized by Sanger sequencing on a
37306l DNA Analyser (Applied Biosystems, Foster City, CA,
USA). Sanger sequencing was also used to double-check
p.Glu227Lys mutation in KCNJ11. A standard protocol was
followed and primer designs and PCR conditions can be provided
upon request. Sequencing reads were assembled and analyzed
with Variant Reporter software (Applied Biosystems).
Linkage Analysis
Two-point and multipoint linkage analyses were performed in
the extended family using both parametric and non-parametric
methods.
For the parametric model, initial genetic data obtained for the
pedigree from a previous genome-wide scan study [7], as well as
the KCNJ11 p.Glu227Lys genotypes, were analyzed using the
MLINK and SIMWALK2 programs, based on several age-
dependent liability classes (LINKAGE package), as previously
described [30]. The model used a disease allele frequency of 0.002
and three age-dependent liability classes: ,13, 13–39, and $40
years, with age-dependent penetrances for one or two copies of the
disease allele of 0.10, 0.60 and 0.90, respectively. The penetrances
for the homozygous non-susceptible genotypes were assumed to be
0.00, 0.03 and 0.03 for the three liability classes, respectively.
We used the program Allegro.2.0 f [31] to compute a non-
parametric linkage (NPL) score, which allowed us to assess linkage
without specifying a mode of inheritance in the extended family.
This statistic is based on the transmission of an allele according to
the genotypes in the family relatives. Thus, a vector of inheritance
is defined, which is used to determine the number of alleles shared
between pairs of affected relatives in the family. Allele frequencies
were estimated with an estimation-maximisation algorithm. The
genetic maps used in the multipoint analyses were built according
to the Genethon data (with the genetic distances estimated in cM
Haldane map).
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